title: In vitro activity of dietary flavonol congeners against human cancer cell lines.
abstract: BACKGROUND
  Flavonoids have physiological activity and a variety of pharmacological properties, including anticancer activity in vitro, but structure-anticancer activity relationships are unclear.
  
  
  OBJECTIVE
  The objectives of this work were to investigate the activity of dietary flavonol congeners against cell lines derived from human solid tumours and to examine whether the in vitro activity was associated with specific structural feature(s) of the molecules.
  
  
  METHODS
  Antiproliferative activity of the flavonol congeners was investigated against eight different human cancer cell lines representing different types of human solid tumour, using the sulforhodamine B (SRB) assay in accordance with the instructions published by the NCI. Cell cycle perturbations caused by the congeners were monitored by flow-cytometric analysis of DNA stained with propidium iodide.
  
  
  RESULTS
  Most of the flavonols examined had weak antiproliferative and cytotoxic activity. Of all the flavonol congeners tested peracetylated tiliroside found to be the most powerful, with significant antiproliferative and cytotoxic activity. Most flavonols induced similar cell cycle perturbations, whereas induction of apoptosis was significant only for cells treated with peracetylated tiliroside.
  
  
  CONCLUSIONS
  These findings indicated that the -OH groups of aromatic ring B were not linked to the cytotoxic and antiproliferative activity of the tested flavonols whereas peracetylation of the glycosides resulted in moderate improvement. In contrast, acetylation of tiliroside esterified with coumaric acid at position 5 of the sugar moiety greatly improved the activity of this congener. Overall, the results of this study suggest a critical role of sugar moiety substituents in the anticancer activity of the flavonols.
authors: Division of Pharmacology-Pharmacotechnology, Biomedical Research Foundation, Academy of Athens, Athens, Greece.
authors: Chrisiida
authors: C
authors: Tsimplouli
authors: Costas
authors: C
authors: Demetzos
authors: Margarita
authors: M
authors: Hadzopoulou-Cladaras
authors: Panayotis
authors: P
authors: Pantazis
authors: Konstantinos
authors: K
authors: Dimas
references: J Pharmacol Exp Ther. 2000 Sep;294(3):837-43
references: 10945831
references: Apoptosis. 2007 Apr;12(4):685-94
references: 17260186
references: Free Radic Biol Med. 1996;20(7):933-56
references: 8743980
references: Clin Cancer Res. 1996 Apr;2(4):659-68
references: 9816216
references: Curr Med Chem Anticancer Agents. 2002 Nov;2(6):691-714
references: 12678721
references: Free Radic Biol Med. 1998 Jul 1;25(1):19-25
references: 9655517
references: Cancer Res. 2005 Feb 1;65(3):1027-34
references: 15705904
references: Bioorg Med Chem. 2006 Jun 1;14(11):3974-7
references: 16524738
references: Leuk Res. 1999 Nov;23(11):1021-33
references: 10576507
references: Bioorg Med Chem. 2006 Sep 1;14(17):6034-42
references: 16723233
references: Pharmacol Rev. 2000 Dec;52(4):673-751
references: 11121513
references: In Vivo. 2005 Sep-Oct;19(5):895-909
references: 16097445
references: Biomed Pharmacother. 2006 Apr;60(3):127-33
references: 16527443
references: Recent Pat Anticancer Drug Discov. 2010 Jun;5(2):152-64
references: 20088766
references: Nat Rev Mol Cell Biol. 2008 Oct;9(10):747-58
references: 18813292
references: Phytomedicine. 2007 Apr;14(4):263-72
references: 16713222
references: Cancer Res. 2005 Apr 15;65(8):3108-16
references: 15833840
references: Curr Drug Metab. 2006 Oct;7(7):729-44
references: 17073577
references: J Pharmacol Exp Ther. 2000 Sep;294(3):830-6
references: 10945830
references: Anticancer Res. 1999 May-Jun;19(3A):2085-8
references: 10470152
references: Cell Mol Life Sci. 1997 Jul;53(7):587-92
references: 9284960
references: Eur J Nutr. 1999 Jun;38(3):133-42
references: 10443335
references: J Nutr. 2005 Mar;135(3):525-31
references: 15735088
references: Pharmacol Res. 2000 Jan;41(1):83-86
references: 10712831